Core Insights - Pharming Group N.V. has announced its financial guidance for 2026, projecting total revenues between US$405 million and US$425 million, representing an 8% to 13% growth [3][7][8] - The company will highlight its advancing clinical-stage pipeline, focusing on two major programs targeting primary immunodeficiencies and mitochondrial diseases during its Investor Day [2][4][6] Financial Guidance - Total revenue guidance for 2026 is set between US$405 million and US$425 million, driven by growth in its commercial products [3][8] - Total operating expenses are expected to be between US$330 million and US$335 million, primarily due to increased R&D expenses related to ongoing clinical trials [7][8] Pipeline Overview - Leniolisib is being developed for primary immunodeficiencies with immune dysregulation, with ongoing Phase II trials expected to yield top-line data in the second half of 2026 [4][5] - Napazimone (KL1333) is being developed for mtDNA-driven mitochondrial disease, with a pivotal clinical trial ongoing and results anticipated in 2027 [6][9] Clinical Programs - Leniolisib is currently approved as Joenja in the U.S. and is the first targeted treatment for activated PI3Kδ syndrome, with potential applicability across broader patient populations [5][6] - Napazimone (KL1333) aims to become the first standard of care for mtDNA-driven mitochondrial disease, addressing significant unmet medical needs [6][9] Investor Day Details - The Investor Day will feature presentations from clinical experts discussing disease biology and the potential impact of Pharming's programs [10][16] - The event is scheduled for February 3, 2026, from 10:00 a.m. to 12:00 p.m. EST, and will be available via webcast [11]

Core Viewpoint - Sanofi has announced a share buyback program of up to €1 billion, set to take place between February 3, 2026, and December 31, 2026 [1] Company Overview - Sanofi is an R&D driven, AI-powered biopharma company focused on improving lives through innovative medicines and vaccines, with a commitment to addressing urgent healthcare and societal challenges [2] Share Buyback Program Details - The share buyback program is authorized for a total consideration of up to €1 billion, with a mandate signed with an investment service provider on February 2, 2026 [1][6]

Core Viewpoint - Avidity Biosciences is set to distribute shares of Atrium Therapeutics to its stockholders as part of a merger with Novartis AG and a spin-off of its early-stage precision cardiology programs [1][2] Company Overview - Avidity Biosciences focuses on RNA therapeutics, specifically Antibody Oligonucleotide Conjugates (AOCs), aiming to improve treatment for diseases previously unreachable with existing RNA therapies [3] - The company has developed a proprietary AOC platform that successfully targets RNA delivery into muscle, with ongoing clinical programs for myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystrophy [3] - Avidity is also advancing two precision cardiology candidates targeting rare genetic cardiomyopathies and expanding its pipeline through partnerships in cardiology and immunology [3] Transaction Details - The record date for the distribution of SpinCo shares is set for February 12, 2026, with stockholders receiving one share of SpinCo for every ten shares of Avidity held [1] - The completion of the merger and spin-off is contingent upon certain closing conditions, including stockholder approval, which may affect the record date [2]

Core Thesis - C4 Therapeutics, Inc. is positioned as a leader in targeted protein degradation (TPD), a novel approach in precision oncology that focuses on eliminating disease-causing proteins rather than merely inhibiting them [3][4] Company Overview - C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic candidates aimed at degrading proteins responsible for diseases [3] - The company's share price was $1.9600 as of January 29th [1] Technology and Innovation - C4's proprietary E3 ligase platform is protected by strong intellectual property and has been validated through partnerships with major pharmaceutical companies like Pfizer and Biogen [4] - The TORPEDO platform allows for rational design and rapid optimization of degraders, which shortens development cycles and enhances competitive advantages [4] Strategic Focus - The company targets orphan oncology indications, such as synovial sarcoma and multiple myeloma, with its BRD9 and IKZF1/3 degraders, CFT8634 and CFT7455, which have received orphan drug designations [5] - This strategic focus enables smaller and faster pivotal trials, regulatory support, and exclusivity-driven economics, providing a sustainable market advantage [5] Financial Management - C4 maintains a lean cost structure and pursues milestone-based partnerships to extend its cash runway without diluting ownership [5] Competitive Landscape - Despite challenges in ligase engineering and scalability, C4's in-house chemistry, clinical networks, and manufacturing capabilities create significant entry barriers for competitors [6] - The company is one of the few independent TPD pure-plays capable of sustained value creation and strategic optionality [7] Upcoming Catalysts - Anticipated catalysts include durable efficacy data in orphan cohorts, positive results from combination therapies with standard-of-care regimens, and milestone payments from partners [6]

Core Thesis - AbbVie Inc. is strategically positioning itself to offset revenue declines from the loss of exclusivity on its arthritis drug Humira by pursuing innovative therapies, including the recent acquisition of Capstan Therapeutics for up to $2.1 billion, which focuses on in vivo CAR-T therapy [2][3][4] Financial Performance - AbbVie Inc.'s share price was $223.01 as of January 30th, with trailing and forward P/E ratios of 166.99 and 15.70 respectively [1] Acquisition and Innovation - The acquisition of Capstan Therapeutics provides AbbVie access to an early-stage in vivo CAR-T therapy that aims to reprogram immune cells using lipid nanoparticles, potentially offering a transformative treatment for autoimmune diseases [3][4] - This approach eliminates the need for hospital-based cell manufacturing and could replace years of symptom-controlling treatments [4] Revenue Potential - AbbVie aims to generate approximately $10 billion in new immunology revenue by 2030, with in vivo CAR-T therapies viewed as a significant contributor if early trials show safe and durable remissions [4] - Analysts believe that the acquisition reflects AbbVie's ability to identify and integrate high-value biotech assets that can drive cash flows while addressing unmet medical needs [5] Strategic Growth - AbbVie's track record of advancing complex therapies from acquisition to commercialization gives investors confidence in the potential success of in vivo CAR-T [5] - The initiative strengthens AbbVie's immunology pipeline and illustrates a strategy of leveraging cutting-edge cell therapies to maintain growth amid patent expirations and competitive pressures [5] Historical Context - Previous bullish coverage highlighted AbbVie's strong pipeline execution and growth from products like Skyrizi and Rinvoq, with stock appreciation of approximately 12.36% since May 2025 due to operational achievements [6]

Core Insights - The call discusses data presented at the Theranostics World Conference in South Africa regarding MP0712, a DLL3 targeting radiotherapeutic [2] - The data includes clinical imaging and dosimetry results from a named patient access program under South Africa's Section 21 of the Medicines and Related Substances Act [2] Company Information - The presentation is led by Seth Lewis, the Head of Investor Relations and Strategy, indicating a structured approach to investor communication [2] - The clinical study was supervised by Dr. Mike Sathekge, a prominent figure in Nuclear Medicine at the University of Pretoria and Steve Biko Academic Hospital [3]

NEEDHAM, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that on January 31, 2026, the Compensation Committee of Candel’s Board of Directors (the Board) granted to one new employee, stock options to purchase an aggregate of 6,600 shares of the Company’s common stock, with a per share exercise price of ...

Core Insights - KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) is recognized as one of the 20 Best Biotech Stocks Under $20 to buy now, ranking twelfth on the list [1] - Analysts from TD Cowen and H.C. Wainwright have raised their price targets for KALV, indicating strong confidence in the company's future performance [2][1] Analyst Ratings - TD Cowen analyst Stacy Ku increased the price target for KALV from $30 to $35 while maintaining a Buy rating, following an update to the financial model ahead of the fourth-quarter results [1] - H.C. Wainwright analyst Andrew Fein raised the price target from $27 to $37, also maintaining a Buy rating, citing confidence from the company's fiscal 2025 EKTERLY revenue [2] Company Overview - KalVista Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing small-molecule protease inhibitors for rare diseases, including hereditary angioedema and diabetic macular edema [3] - The company aims to provide oral and targeted therapies to enhance patient outcomes and quality of life [3]

As filed with the U.S. Securities and Exchange Commission on February 2, 2026. Registration Number 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________ FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 _______________________________ SALSPERA, INC. (Exact Name of Registrant as Specified in its Charter) _______________________________ Delaware 2834 87-4698872 (State or other jurisdiction of incorporation or organization) (Primary Standard ...

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. TenNor Therapeutics (Suzhou) Limited 丹諾醫藥(蘇州)股份有限公司 (A joint stock company incorporated in the People's Republic of China with limited liability) ...